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Abstract
Lantibiotics are small peptide antibiotics that contain the characteristic thioether amino acids lanthionine and
methyllanthionine. As ribosomally synthesized peptides, lantibiotics possess biosynthetic gene clusters which contain
the structural gene (lanA) as well as the other genes which are involved in lantibiotic modification (lanM, lanB, lanC, lanP),
regulation (lanR, lanK), export (lanT(P)) and immunity (lanEFG). The lantibiotic mersacidin is produced by Bacillus sp. HIL Y-
85,54728, which is not naturally competent.
Methodology/Principal Findings: The aim of these studies was to test if the production of mersacidin could be transferred
to a naturally competent Bacillus strain employing genomic DNA of the producer strain. Bacillus amyloliquefaciens FZB42
was chosen for these experiments because it already harbors the mersacidin immunity genes. After transfer of the
biosynthetic part of the gene cluster by competence transformation, production of active mersacidin was obtained from a
plasmid in trans. Furthermore, comparison of several DNA sequences and biochemical testing of B. amyloliquefaciens FZB42
and B. sp. HIL Y-85,54728 showed that the producer strain of mersacidin is a member of the species B. amyloliquefaciens.
Conclusions/Significance: The lantibiotic mersacidin can be produced in B. amyloliquefaciens FZB42, which is closely related
to the wild type producer strain of mersacidin. The new mersacidin producer strain enables us to use the full potential of the
biosynthetic gene cluster for genetic manipulation and downstream modification approaches.
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Introduction
The lantibiotic (i.e. lanthionine-containing antibiotic) mersaci-
din is an antimicrobial peptide that consists of 20 amino acids. The
producer strain of mersacidin, Bacillus sp. HIL Y-85,54728 [1], has
not yet been closely characterized. The structural gene (mrsA) and
the genes for modification enzymes, transporters and producer
self-protection are encoded on a 12.3 kb biosynthetic gene cluster
on the chromosome of the producer strain [2]. Moreover, three
regulatory genes are present in the gene cluster. The two-
component regulatory system MrsR2/K2 is mainly involved in
immunity and induction of mersacidin biosynthesis in the presence
of mersacidin by a quorum sensing mechanism [3]. A further
single regulatory protein, MrsR1, is encoded downstream of mrsA
and is essential for mersacidin production [4]. Mersacidin inhibits
the growth of gram-positive bacteria by binding to the cell wall
precursor lipid II and thereby inhibiting cell wall biosynthesis [5].
Production of mersacidin and genetically engineered mersacidin
peptides has so far been performed in variants of the original
producer strain, Bacillus sp. HIL Y-85,54728. Production of
engineered peptides was obtained either in trans after inactivation
of mrsA by introduction of a stop codon [6] or in cis after double
homologous recombination [7]. However, transformation of the
producer strain with exogenous plasmids could only be achieved
by protoplast transformation or electroporation and both methods
yielded only low transformation frequencies. Therefore, the aim of
these studies was to build an expression system for mersacidin in a
naturally competent Bacillus strain in synthetic medium and exploit
competence transformation as an efficient method for the transfer
of the biosynthetic gene cluster and plasmids harboring mrsA.
Successful heterologous production has previously been shown
for several lantibiotics, e. g. subtilin and nisin by B. subtilis 168
[8,9], lacticin 3147 by Enterococcus faecalis [10], or epicidin 280 by
Staphylococcus carnosus [11]. Very recently, production of active
lichenicidin has even been achieved in Escherichia coli [12].
However, heterologous production of a lantibiotic cannot be
taken for granted and remains difficult. For example, epicidin 280
and Pep5 are two closely related lantibiotics, but Pep5 shows a
higher antibacterial activity than epicidin 280. In contrast to
epicidin 280 [11], Pep5 cannot be expressed in S. carnosus, which is
susceptible to this agent in the nanomolar range, indicating that
the toxicity of the product may be a problem here (G. Bierbaum,
unpublished data). Therefore, for successful and high-level
expression of mersacidin in a heterologous host, two conditions
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the biosynthetic gene cluster to the new host. The genome of
Bacillus amyloliquefaciens FZB42, a competent plant-growth promot-
ing rhizobacterium, has recently been sequenced. The part of the
mersacidin biosynthetic gene cluster, that is devoted to producer
self-protection, is already present in this organism [13] making it
an ideal candidate for the transfer of the biosynthetic genes. Here
we show that production of mersacidin is possible in B.
amyloliquefaciens FZB42 and that the mersacidin producer strain
itself is a member of this species.
Results and Discussion
B. amyloliquefaciens FZB42 is immune to mersacidin
Analysis of the complete genome sequence of B. amyloliquefaciens
FZB42 [13] had shown, that mrsFGE, which encode an ABC
transporter that inhibits binding of mersacidin to the cells [4], and
mrsK2R2, the genes of a two component system that induces
expression of mrsFGE in the presence of mersacidin [3], are present
in this organism (Fig. 1). These genes are located at the same site as
in the original producer strain of mersacidin, i. e. between ycdJ and
fbaB [2]. A detailed comparison showed that the encoded proteins
share at least 98 % amino acid identity (two exchanges in MrsE
and MrsF, one exchange in MrsR2 and four exchanges in MrsK2),
with the exception of the N-terminus of MrsG. However,
resequencing of the wild type producer indicated that a thymidine
residue in position 980 was missing in the original sequence of
mrsG. After sequence correction, the MrsG amino acid sequences
were identical. In the intergenic region between mrsE and fbaB,a
short sequence of 147 bp is inserted in the genome of B.
amyloliquefaciens FZB42 (bp 3774591 to 3774738) that is not present
in the producer strain of mersacidin and did not yield any hits in
the databases. This sequence is flanked by two distinct regions with
sequence similarity to the mersacidin gene cluster. The upstream
38 bp region is similar to the sequence found downstream of mrsE,
i. e. the sequence upstream of the putative mrsA operator. The
89 bp region found downstream of the 147 bp insert is homolo-
gous to the sequence downstream of mrsT, contains the inverted
repeat that is thought to delimit the mersacidin biosynthetic gene
cluster and is not present in B. amyloliquefaciens DSM 7
T. This
might indicate that the biosynthetic part of the gene cluster was
lost from B. amyloliquefaciens FZB42 during evolution.
A previous comparison of minimum inhibitory concentration
(MIC) values of the wild type producer and an mrsK2R2 knockout
clone, which does not express the mersacidin immunity genes
mrsFGE, had demonstrated that expression of mrsK2R2FGE
increased the resistance to mersacidin about threefold [4]. MIC
determinations of the wild type producer (25 mg/l) and B.
amyloliquefaciens FZB42 (25 mg/l) demonstrated that B. amylolique-
faciens FZB42 was at least as resistant to mersacidin as the producer
strain and therefore this organism was chosen as amenable to
mersacidin production.
Reconstitution of mersacidin production in B. amyloliquefaciens
FZB42
In order to transfer the biosynthetic part of the mersacidin
biosynthetic gene cluster into B. amyloliquefaciens FZB42, chromo-
somal DNA of Bacillus sp. HIL Y-85,54728 Rec1 was utilized. This
strain harbors the complete mersacidin gene cluster including the
operator sequence, apart from mrsA and its promoter that have
been replaced by an erythromycin resistance cassette [2]. There-
fore, the use of erythromycin as a selection marker for successful
integration of the gene cluster was possible during transformation
experiments. After a competence transformation, 15 erythromycin
resistant colonies were isolated and insertion of the biosynthetic
part of the mersacidin biosynthesis gene cluster was confirmed by
PCR, employing the primers mrsE681.f and ermB665.r annealing
in mrsE and ermB as well as mrsT2251.f and fbaB283.r annealing
in mrsT and fabB. A PCR of comK, employing primers located in
the intergenic region (FZBfor, FZBrev) that did not match the
Figure 1. The (partial) mersacidin biosynthesis gene clusters of the mersacidin producer B. sp. HIL Y-85,54728, B. amyloliquefaciens
FZB42 and its derivatives. The mersacidin gene cluster of the original producer strain B. sp. HIL Y-85,54728 (A) consists of the immunity genes
mrsFGE (green colors), the structural gene mrsA (light blue), the modification enzymes mrsD and mrsM (dark blue colors), the exporter containing a
protease domain mrsT (purple) and the regulatory genes mrsR1, mrsR2 and mrsK2 (yellow and orange colors). The genome of B. amyloliquefaciens
FZB42 (B) harbors a partial mersacidin gene cluster consisting of the immunity genes mrsFGE and the regulatory genes mrsK2 and mrsR2. The genes
are found at the same site as in the original producer strain, i. e. between ycdJ and fbaB. In the mutant strain B. amyloliquefaciens mrs1 (C), a partial
completion of the mersacidin gene cluster was reached by competence transformation using genomic DNA of a mersacidin deletion mutant (B. sp.
HIL Y-85,54728 Rec1). An erythromycin resistance (ermB) cassette substituting mrsA served as selection marker. mrsR1 is most probably not
transcribed in this mutant because of a polar effect. The completion of the mersacidin gene cluster in B. amyloliquefaciens mrs1 pPAR1 (D) was
achieved in trans by transformation with the plasmid pPAR1, carrying the structural gene mrsA and mrsR1, yielding B. amyloliquefaciens mrs1 pPAR1.
doi:10.1371/journal.pone.0022389.g001
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clones were indeed B. amyloliquefaciens FZB42 transformants and
did not derive from spores of the producer strain. Subsequently,
one of these clones, B. amyloliquefaciens FZB42 mrs1, was
transformed with pPAR1 [3], which harbors mrsA and mrsR1,b y
competence transformation. The regulator MrsR1 is essential for
mersacidin biosynthesis [4] and is transcribed from the mrsA
promoter (Bierbaum, unpublished results).
In order to demonstrate the expression of mersacidin, MALDI-
TOF analysis of the culture supernatant of B. amyloliquefaciens mrs1
pPAR1 was performed and spectra were compared to those of B.
amyloliquefaciens FZB42 (wild type) as well as the mrs1 strain,
missing mrsA (Fig. 2). The typical mersacidin masses [1826 Da:
mersacidin + H, 1848 Da: mersacidin + Na and 1864 Da:
mersacidin + K] were detected in the culture supernatant of the
strain harboring pPAR1, indicating expression of fully modified
mersacidin. In contrast, the spectra of B. amyloliquefaciens FZB42
and of B. amyloliquefaciens mrs1 did not show any mersacidin-
related mass peaks.
On the other hand, in agar well diffusion assays with
supernatants of cultures incubated in the absence of chloram-
phenicol, the inhibition zones of B. amyloliquefaciens mrs1 pPAR1
against M. luteus, S. aureus SG511 and Bacillus megaterium were not
significantly larger than those produced by B. amyloliquefaciens
FZB42 or B. amyloliquefaciens mrs1. The reason for this observation
was that B. amyloliquefaciens FZB42 is able to produce an array of
antimicrobial and antifungal substances including polyketides
(bacillaene, difficidin, macrolactin), lipopeptides (surfactin, fengy-
cin, bacillomycin D), two siderophores (bacillibactin, product of nrs
cluster), the antimicrobial dipeptide bacilysin as well as the
thiazole/oxazole containing antibiotic plantazolicin [14,15].
Comparative MALDI-TOF spectra of B. amyloliquefaciens FZB42
and its mutant strains indeed indicated the presence of the
lipopeptide surfactin and the antifungal compounds fengycin and
bacillomycin D in culture supernatants of all tested B. amylolique-
faciens strains (data not shown). The activity of surfactin was also
detected by hemolysis on Columbia blood agar plates. In
conclusion, the antimicrobial activity of mersacidin was probably
masked by the activity of surfactin in the agar well diffusion assays.
The production of several antibacterial products by Bacillus strains
is far from unusual. For example, secondary antibacterial
compounds are also detected in the culture supernatants of the
producer strain of mersacidin (Bierbaum, unpublished results) and
even B. subtilis 168 - in spite of the mutation in sfp that inhibits
production of the lipopeptides encoded in the genome [16]
(surfactin [17] and plipastatin/fengycin [18]) - is still able to
excrete at least four other antibacterial compounds, i. e. sublancin
168 [19], subtilosin A [20], bacilysocin [21] and bacilysin [22].
In order to demonstrate that the mersacidin produced by B.
amyloliquefaciens mrs1 pPAR1 was correctly modified and showed
antimicrobial activity, it was partially purified by two consecutive
HPLC runs from cultures grown in the presence of chloramphen-
icol. The HPLC fractions that were active against M. luteus and
that showed the typical adsorption spectrum of mersacidin were
further analyzed by MALDI-TOF and showed the presence of the
typical mass signals (Fig. 3). These results indicated B. amylolique-
Figure 2. MALDI-TOF mass spectra of pure mersacidin and culture supernatants of B. amyloliquefaciens clones. Panel (A) shows pure
mersacidin (control). The spectra of culture supernatants of B. amyloliquefaciens FZB42 (B) as well as of B. amyloliquefaciens mrs1 (C), which harbor
only a part of the mersacidin gene cluster or miss the structural gene mrsA, respectively, show no mersacidin production. In contrast, the culture
supernatant of B. amyloliquefaciens mrs1 pPAR1 (D) is characterized by the presence of the typical mersacidin-related mass signals [1826 Da:
mersacidin + H, 1848 Da: mersacidin + Na and 1864 Da: mersacidin + K] which demonstrate the production of mersacidin by this strain.
doi:10.1371/journal.pone.0022389.g002
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mersacidin.
The producer strain of mersacidin belongs to the species
B. amyloliquefaciens
Upon comparison of various DNA sequences (yvnB, czcO, hpr,
baeD, hemE,a n dcomK) obtained from the producer strain of
mersacidin to the sequences of the B. amyloliquefaciens FZB42 genome
in NCBI, a high similarity between both strains became obvious.
Table 1 demonstrates that all sequences, including intergenic
regions, showed about 98.5 % nucleotide sequence identity to those
of B. amyloliquefaciens FZB42 and about 93.5 % identity to the
sequences of the type strain B. amyloliquefaciens DSM 7
T, whereas the
identity to B. subtilis 168 was considerably lower (77.4 %).
During BLAST searches, the genome sequence of B. amyloli-
quefaciens FZB42 always showed the highest similarity to the
sequence of the producer strain. B. amyloliquefaciens DSM 7 scored
second, with the exception of the czcO region which seems to be
partially missing in this strain, followed by B. subtilis 168 in third
position (with the single exception of hemE, here B. subtilis W23
scored third with 168/212 identical bases).
The presence of baeD showed that Bacillus sp. HIL Y-85,54728
carries at least parts of the bacillaene gene cluster that was
described for B. amyloliquefaciens FZB42 [13] and B. amyloliquefaciens
DSM 7
T [23]. A biochemical identification test demonstrated that,
in contrast to B. subtilis 168, B. amyloliquefaciens FZB42 and Bacillus
sp. HIL Y-85,54728 both were able to metabolize xylose, lactose
and starch and did not grow at 50uC nor in the presence of 10 %
NaCl. Furthermore, both strains did not produce acid from
trehalose and mannitol. The only difference between B. amyloli-
quefaciens FZB42 and Bacillus sp. HIL Y-85,54728 was the absence
of gelatinase in the latter strain. 16S rRNA sequencing was
performed with a PCR product that had been obtained using
chromosomal DNA of Bacillus sp. HIL Y-85,54728 as a template.
An NCBI BLAST search yielded a close similarity to B.
amyloliquefaciens FZB42 16S rRNA (Table 2), indicating that
Bacillus sp. HIL Y-85,54728 belongs to the species B. amylolique-
faciens. This was confirmed by the sequence of the gyrase gene gyrA
Figure 3. Purification of mersacidin from culture supernatant of B. amyloliquefaciens mrs1 pPAR1. The culture supernatant of B.
amyloliquefaciens mrs1 pPAR1 was applied to a Poros RP-HPLC column and eluted in a gradient of 30 % to 42 % acetonitrile (containing 0.1 % TFA).
Active fractions were pooled and lyophilized. The resulting lyophilizate was resuspended in 5 % acetonitrile and applied to a Nucleosil RP-C18 column
(A). The antimicrobial activity of the fractions was assayed in agar well diffusion tests against M. luteus (diameter 3.2 cm) (C) and analyzed by MALDI-
TOF (B). Active fractions eluted after 20 min in a gradient of 50 – 65 % acetonitrile (0.1 % TFA) and were characterized by the presence of a peak with
1826.339 Da representing mersacidin.
doi:10.1371/journal.pone.0022389.g003
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mersacidin should be renamed ‘‘B. amyloliquefaciens HIL Y-
85,54728’’.
B. amyloliquefaciens FZB42 was isolated from the plant rhizo-
sphere and has recently been defined as the type strain of a group
of growth-promoting plant associated B. amyloliquefaciens strains (B.
amyloliquefaciens subsp. plantarum) [24]. In addition to their ability to
colonize plant roots, the members of the plantarum subspecies are
discriminated from the subspecies B. amyloliquefaciens subsp.
amyloliquefaciens by differences in the gyrA and cheA nucleotide
sequence, hydrolysis of cellulose and an increased ability to
produce nonribosomal secondary metabolites like fengycin and
difficin [24]. In a taxonomic tree that was calculated from the gyrA
nucleotide sequences of the mersacidin producer and different
members of the genus Bacillus, the producer strain is found in the
cluster formed by the members of the plantarum subspecies,
suggesting a close association between the mersacidin wild type
producer and these strains (Fig. 4). The similarity was not confined
to the gyrA gene but was also reflected by the higher overall
nucleotide sequence identity (98.5 %) of the mersacidin wild type
producer and B. amyloliquefaciens subsp. plantarum FZB42 in
comparison to the value reached by B. amyloliquefaciens subsp.
amyloliquefaciens DSM 7
T (93.5 %) (Table 1).
AdistinguishingfeatureofthesubspeciesB.amyloliquefacienssubsp.
plantarum is their ability to colonize Arabidopsis roots [24]. In fact,
nearly all members of this subspecies were isolated from plants,
plant roots or like B. amyloliquefaciens FZB42 from infested soil. The
only exception is represented by strain UCMB5113 that was
isolated from soil. In contrast, the producer strain of mersacidin
originates from soil of a salt pan in Mulund, India, and
unfortunately a plant association of the original isolate was not
mentioned in the first report [1]. However, the strain did not grow
in the presenceof 10 % saltin the laboratory, indicating that the salt
pan might not be its natural biotope and that its presence in the
sample might rather be due to its ability to form long-lived spores.
In conclusion, we could show here that it is possible to produce
mersacidin in B. amyloliquefaciens FZB42. The successful production
of fully modified and active mersacidin by this strain provides an
appropriate in vivo expression system for the construction and
expression of mersacidin analogs. The vast array of antibacterial
and antifungal compounds that is already excreted by this
organism is thought to provide competitive advantage in the
rhizosphere [25]. It also harbors genes which are nearly identical
to the immunity genes of mersacidin and which will afford
additional protection against competing strains that excrete this
lantibiotic. The strategy employed here, i. e. to use an organism
that already possesses the immunity genes of a lantibiotic for
production of the same substance, proved successful and led to the
production of active and fully modified mersacidin.
Materials and Methods
Strains, plasmids, culture conditions and media
All bacterial strains and plasmids used in this study are listed in
table 3. Strains were stored as 50 % glycerol stocks at 280uC.
Bacillus strains were cultured in tryptic soy broth (TSB, Oxoid,
Wesel, Germany) or on tryptic soy agar. Escherichia coli strains were
cultivated in LB. All cultures were maintained at 37uC. For
Table 1. Results of discontiguous megablasts employing nucleotide sequences of Bacillus sp. HIL Y-85,54728.
gene B. amyloliquefaciens FZB42 B. amyloliquefaciens DSM 7
T B. subtilis 168
identical bases/
total bases
percent
identity
identical bases/
total bases
percent
identity
identical bases/
total bases
percent
identity
yvnB 628/638 98.4 595/638 93.2 464/638 72.7
czcO 747/758 98.5 164/192 85.4 651/788 82.6
baeD 337/343 98.2 319/343 93.0 174/240 72.5
yhaI, hpr 768/779 98.5 746/779 95.7 632/782 80.8
hemE 217/220 98.6 216/220 98.1 167/212 78.7
comK 802/814 98.5 780/814 95.8 559/720 77.6
mean value 98.5 93.5 77.4
doi:10.1371/journal.pone.0022389.t001
Table 2. Comparison of the sequences of the Bacillus sp. HIL Y-85,54728 16S rRNA genes with all rrn paralogs of Bacillus
amyloliquefaciens DSM 7
T, Bacillus amyloliquefaciens FZB42 and Bacillus subtilis 168.
strain/nucleotide position
a 181 186 203 286 466 473 484
B. sp. HIL Y-85,54728 C/G
b C/T G A/G G A C
B. amyloliquefaciens FZB42 G C/T G A/G G A C
B. amyloliquefaciens DSM 7
T CTA / G GGAC
B. subtilis 1 6 8 GAAAAGT
aThe nucleotide positions correspond to [29]. All other bases are conserved between the four strains.
bThe PCR product was directly sequenced, therefore, it contained all rrn paralogs and gave three mixed positions. An alignment of all seven paralogs of the B.
amyloliquefaciens FZB42 16S rRNA with the sequence of the producer strain showed that two of the three mixed positions of Bacillus sp. HIL Y-85,54728 vary in B.
amyloliquefaciens FZB42 in the same manner. The third mixed position (181) contained the C that is present in all rrn paralogs of B. amyloliquefaciens DSM 7
T and the G
that is found in all paralogs of B. amyloliquefaciens FZB42.
doi:10.1371/journal.pone.0022389.t002
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growth media (ampicillin, 40 mg/ml; erythromycin, 25 mg/ml;
chloramphenicol, 20 mg/ml).
Purification of nucleic acids and sequencing
Genomic DNA was prepared using the PrestoSpinD Bug Kit
according to the recommendations of the supplier (Molzym,
Bremen, Germany). Plasmid DNA was isolated using the Gene-
Jet
TM Plasmid Miniprep Kit (Fermentas, St. Leon-Rot, Germany).
All nucleic acids were analyzed by agarose gel electrophoresis and
by spectrophotometry (Nanodrop Technologies, Wilmington,
USA).
DNA sequencing was performed by Sequiserve (Vaterstetten,
Germany) or Seqlab (Go ¨ttingen, Germany). Plasmid DNA and
Figure 4. Phylogenetic tree based on the partial nucleotide sequence of the gyrA gene. The tree was calculated based on the gyrA
nucleotide sequences of the mersacidin producer (BHILY, marked by a red box) and different members of the genus Bacillus (NCBI accession numbers
in brackets) [B. amyloliquefaciens = BAMY strains: FZB42 (CP000560), CAUB946 (FN652789), S23 (FN652780), ATCC15841 (FN662838), DSM7
(FN597644), NAUB3 (FN652783), NAUB55 (FN652801), UCMB5113 (AY212974); B. licheniformis = BLIC strains: MY75 (EU073420), DSM13 (BLi00007),
CICC10085 (GQ355995); B. subtilis = BSUB strains: 168 (BSU00070), DV1-B1 (EF134416) and B. cereus = BCER strain: ATCC14579 (BC0006)]. The
mersacidin wild type producer is placed among the members of the subspecies B. amyloliquefaciens subsp. plantarum; it does not belong to the
subspecies amyloliquefaciens that consists of strains closely related to the type strain B. amyloliquefaciens DSM 7
T. It is also clearly not a member of
the species B. subtilis, B. cereus or B. licheniformis.
doi:10.1371/journal.pone.0022389.g004
Table 3. Strains and plasmids used in this study.
Microorganism/plasmid Function Source/reference
E. coli K12 strains Cloning hosts
B. subtilis 168 Type strain of B. subtilis ATCC 23857
[30]
B. sp. HIL Y-85,54728 Wild type mersacidin producer strain, strain collection of Sanofi-Aventis
(Frankfurt, Germany), no. FH 1658
[1]
B. sp. HIL Y-85,54728 Rec1 Mersacidin wild type producer deletion mutant: mrsA replaced by ermB,
no mersacidin production
[2]
B. amyloliquefaciens FZB42 Wild type strain, carrying the 59 part of the mersacidin gene cluster (mrsKR2FGE) [13]
B. amyloliquefaciens mrs1 Mutant strain carrying the mersacidin gene cluster; mrsA is replaced by ermB this study
M. luteus ATCC 4698 Indicator strain ATCC 4698
S. aureus SG511 Indicator strain [31]
B. megaterium KM Indicator strain ATCC 13632
pCU1 Shuttle vector [32]
pPAR1 pCU1 harboring the promoter of mrsA, mrsA and the regulator gene mrsR1 [3]
doi:10.1371/journal.pone.0022389.t003
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Germany). Primers used for PCR analyses are listed in table 4.
Sequencing primers were designed using the Primer3: WWW
primer tool (http://biotools.umassmed.edu/bioapps/primer3_www.cgi).
Construction of the mersacidin producing B. amyloliquefaciens
FZB42 mutants
The biosynthetic part of the mersacidin gene cluster was
transferred to B. amyloliquefaciens FZB42 by competence transfor-
mation [26] using genomic DNA of the strain B. sp. HIL Y-
85,54728 Rec1, which harbors a selection marker (ermB resistance
cassette) instead of mrsA. Transformants were selected on TSA
(0.3 mg/ml erythromycin) and were subsequently cultured on TSA
containing erythromycin at a final concentration of 25 mg/ml.
The transfer of the gene cluster was confirmed by PCR using
primer combinations that anneal within ermB (ermB665.r), mrsE
(mrsE681.f), mrsT (mrsT2251.f) and the downstream coding ORF
fbaB/iolJ (fbaB283.r) (see Fig. 1). To exclude the possibility that
these colonies might derive from germinated spores of Bacillus sp.
HIL Y-85,54728 Rec1 that had not been eliminated during the
gDNA preparation, differential PCRs were performed using the
comK primers FZBfor and FZBrev. The 39 ends of these primers
anneal to single nucleotide polymorphisms of the sequence of B.
amyloliquefaciens FZB42, but not to those of B. sp. HIL Y-85,54728.
The resulting clone was named B. amyloliquefaciens mrs1.
For reconstitution of mersacidin production, the mersacidin
structural gene (mrsA) was introduced in trans on the plasmid
pPAR1 by competence transformation, yielding B. amyloliquefaciens
mrs1 pPAR1. The presence of the plasmids as well as the plasmid
integrity was analyzed by plasmid isolation and gel electrophoresis.
Producer self-protection against mersacidin
To test the susceptibility of B. amyloliquefaciens FZB42, B.
amyloliquefaciens mrs1, and B. amyloliquefaciens mrs1 pPAR1 to
mersacidin, the minimal inhibitory concentration (MIC) of
mersacidin was determined by arithmetic broth microdilution.
Serial twofold dilutions of mersacidin were prepared in polystyrene
round bottom microtiter plates (Greiner, Frickenhausen, Ger-
many) using half concentrated Mueller Hinton II broth (Difco,
Detroit, USA) containing 1 mM CaCl2. An inoculum of
5610
5 CFU/ml was employed in a final volume of 200 ml. The
MICs were calculated from the lowest concentration of mersacidin
resulting in the complete inhibition of visible bacterial growth after
16 hours of incubation at 37uC and compared to the MIC of the
mersacidin producer B. sp. HIL Y-85,54728.
Mersacidin production by Bacillus amyloliquefaciens mrs1
pPAR1
The production of mersacidin by B. amyloliquefaciens mrs1
harboring pPAR1 was assayed in 50 ml synthetic medium (2 x
BPM) [2] in the presence of chloramphenicol. The cells were
grown for 24 hours at 37uC with agitation (180 rpm). For further
analysis the culture supernatant was sterilized by filtration and
stored at 220uC. The detection of antimicrobial activity in 50 ml
of culture supernatant and HPLC fractions was performed by agar
well diffusion assays on Mueller-Hinton agar II plates (Difco,
Detroit, USA) seeded with the indicator strains Micrococcus luteus
ATCC 4698, Bacillus megaterium KM and Staphylococcus aureus
SG511 in wells with a diameter of 7 mm. After incubation at 37uC
overnight, the growth inhibition zones were measured.
In order to remove the chloramphenicol and other antibiotics
excreted by B. amyloliquefaciens FZB42, 5 ml of the culture
supernatant containing 0.1 % trifluoroacetic acid (TFA, Sigma-
Aldrich,Taufkirchen,Germany)wereappliedto aPorosRP-HPLC-
column (10R2, 10064.6 mm Perseptive Biosystems, Freiburg,
Germany) and eluted in a gradient of 30 % to 42 % acetonitrile
(containing 0.1 % TFA). The peaks were detected measuring the
absorbance at 210 or 220 and 266 nm. The fractions were collected
and assayed for the antimicrobial activity against M. luteus ATCC
4698 in agar well diffusion assays. The active fractions of 85 ml of
culture supernatant were lyophilized and purified further using an
RP C-18 column (Nucleosil-100-C18, 25064.5 mm; Schambeck
SFD GmbH, Bad Honnef, Germany) with a gradient of 50 to 65 %
acetonitrile (containing 0.1 % TFA). For MALDI-TOF analysis
(Bruker Biflex, Bruker Daltonics, Bremen, Germany) of culture
supernatant and active HPLC fractions, 20 ml of each fraction were
concentrated 1:10 using a rotational Vacuum Concentrator (RVC
2–18, Christ, Osterode, Germany). Then, a 1 ml sample was mixed
with 2 ml matrix (alpha-cyano-4-hydroxycinnamic acid in acetoni-
trile: 0.1 % TFA in water, 1:3). The mixtures were spotted onto the
MALDI target and air-dried. Mass spectra were measured in
positive ion mode in the range of 500 to 4000 Da and analyzed by
Flexanalysis 2.0 (Bruker Daltonics).
Species identification of B. sp. HIL-Y-85,54728
The abilities of the wild type mersacidin producer strain, B.
amyloliquefaciens FZB42 and B. subtilis 168 to ferment dextrose,
maltose, lactose, sucrose, xylose, trehalose, mannitol and starch, to
reduce sulfur and nitrate and to hydrolyze tryptophan and gelatin
were compared using a conventional biochemical identification
test. All inoculated tubes were incubated at 37uC for 24 h.
Table 4. Primers used in this study.
Primer Gene Sequence Source
16s1550.r 16sRNA genes (rrn), B. amyloliquefaciens AAGGAGGTGATCCAGCCG [27] modified
16s9.f 16sRNA genes (rrn), B. amyloliquefaciens AGAGTT TGATCCTGGCTCAG [27] modified
ermB665.r ermB CAATTTAAGTACCGTTACTTATGAGC this study
fbaB283.r fbaB, B. amyloliquefaciens FZB42 CTCCCGCATGACTGATATTCCTC this study
gyrA_F gyrA, B. amyloliquefaciens FZB42 CAGTCAGGAAATGCGTACGTCCTT [28]
gyrA_R gyrA, B. amyloliquefaciens FZB42 CAAGGTAATGCTCCAGGCATTGCT [28]
FZBfor comK, B. amyloliquefaciens FZB42 ATGGGGTCGAAGGTCATTGAG this study
FZBrev comK, B. amyloliquefaciens FZB42 CAGCTCCCGCAAAATAAAGTCG this study
mrsE681.f mrsE, mersacidin gene cluster TGTCTCGGTCTCCTGGTTTACG this study
mrsT2251.f mrsT, mersacidin gene cluster GGATAGACAGAAAGCTACGCTGC this study
doi:10.1371/journal.pone.0022389.t004
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temperature (50uC) as well as motility were tested. The PCR
product of the 16S rRNA genes was sequenced using the primers
16s9.f and 16s1550.r [27]. The gene coding for the gyrase subunit
A( gyrA) was partially sequenced employing the primers gyrA_F
and gyrA_R [28].
Bioinformatic tools and nucleotide sequence accession
numbers
The sequences of the chromosome of B. subtilis 168 and B.
amyloliquefaciens FZB42 are deposited in the NCBI database
CoreNucleotide under the accession numbers NC_000964 and
NC_009725, respectively. The sequence of the mersacidin gene
cluster has the accession number AJ250862. Further sequences of
the mersacidin producer strain have been deposited at NCBI
under the following accession numbers: yvn, JF519627; czcO,
JF519628; hpr, JF519629; baeD, JF519630; hemE, JF519631; comK,
JF519632; gyrA, JF519633.
Blasts were performed at the NCBI nucleotide website (http://
blast.ncbi.nlm.nih.gov/Blast.cgi). ClustalW2 (http://www.ebi.ac.
uk/Tools/msa/clustalw2/) and ClustalW 2.0.12 (http://mobyle.
pasteur.fr/cgi-bin/portal.py#forms::clustalw-multialign) were em-
ployed for multi sequence alignments of gyrA and calculation of the
phylogenetic tree.
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